Lupus & antiphospholipid syndrome
Anifrolumab in systemic lupus erythematosus: real-world experience from a single academic tertiary care centre
Authors' conclusion
In our real-world experience, anifrolumab achieved sustained remission after just 3 months of treatment and a significant reduction in disease activity in most patients.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients starting anifrolumab per current guidelines (EULAR 2024), German academic tertiary care centre
- Participants
- 26 patients
- Exposure
- Anifrolumab treatment: baseline vs follow-up
- Anifrolumabn = 26
- Outcome
- Disease activity (SLEDAI-2K), baseline vs 3 months, mean ± SD
- Follow-up
- 3 months
Methodological detailssingle-centre, real-world
- Single-centre
- Real-world
Main finding
As reported in the abstract
Baseline
6.0
SD 3.9
3 months
2.8
SD 2.6
P ≤ 0.001
Observational data: associations, not effects.
Further findings
Mucocutaneous manifestations, fatigue, arthritis/arthralgia
- Mucocutaneous manifestations responded quickly; significant improvements in fatigue and arthritis/arthralgia
Response by prior therapies or disease duration
- Favourable response also in patients with previous therapies or long disease duration
GC dose
- Reduction in GC dose
Safety
Safety and tolerability
- Overall, safe and well tolerated
Original publication
Anifrolumab in systemic lupus erythematosus: real-world experience from a single academic tertiary care centre. Clin Exp Rheumatol. Published 15 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →